Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study Article

Full Text via DOI: 10.1158/1538-7445.SABCS18-P6-20-07 Web of Science: 000478677002353

Cited authors

  • Vidal, G.; Kalinsky, K.; Stringer-Reasor, E.; Lynce, F.; Cole, J.; Valdes-Albini, F.; Soliman, H.; Nikolinakos, P.; Silber, A.; DeMichele, A.; Ali, H.; Graham, D.; Giguere, J.; Brufsky, A.; Liang, Y.; Holland, S.; Fiji, G.; O'Keeffe, B.; Gogineni, K.


Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 0008-5472


  • 79


  • 4